Tag: KDC-MN-279

  • Finasteride

    5-alpha-reductase type II inhibitor

    A 4-azasteroid 5-alpha-reductase type II inhibitor; approved for benign prostatic hyperplasia and androgenetic alopecia.

    Abstract

    Finasteride (N-(2-methyl-2-propanyl)-3-oxo-(5-alpha,17-beta)-4-azaandrost-1-ene-17-carboxamide; CAS 98319-26-7; molecular formula C23H36N2O2; molecular weight 372.55) is a 4-azasteroid 5-alpha-reductase inhibitor developed at Merck and approved by the FDA in 1992 (Proscar 5 mg for BPH) and 1997 (Propecia 1 mg for androgenetic alopecia). Mechanism: selective inhibition of 5-alpha-reductase type II isozyme (Ki approximately 10 nM), which converts testosterone to dihydrotestosterone (DHT) in prostate, hair follicle, and skin. Type I 5AR (in liver, skin, and brain) is largely unaffected. Plasma half-life is approximately 6 to 8 hours; metabolism is via CYP3A4. The compound has well-documented sexual side effects (reduced libido, erectile dysfunction in approximately 1 to 5 percent of users) and the controversial post-finasteride syndrome (persistent symptoms after discontinuation, debated as a clinical entity). Used as the reference 5AR-II selective inhibitor in mechanism studies and as a positive control in androgen pathway research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.